ATE238790T1 - Verwendung von pramipexole als neuroschutzmittel - Google Patents

Verwendung von pramipexole als neuroschutzmittel

Info

Publication number
ATE238790T1
ATE238790T1 AT95942961T AT95942961T ATE238790T1 AT E238790 T1 ATE238790 T1 AT E238790T1 AT 95942961 T AT95942961 T AT 95942961T AT 95942961 T AT95942961 T AT 95942961T AT E238790 T1 ATE238790 T1 AT E238790T1
Authority
AT
Austria
Prior art keywords
pramipexole
neuroprotective agent
neuroprotective
agent
provides
Prior art date
Application number
AT95942961T
Other languages
English (en)
Inventor
Edward Dallas Hall
Voigtlander Philip F Von
Frank A Rohde
Original Assignee
Upjohn Co
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Boehringer Ingelheim Kg filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE238790T1 publication Critical patent/ATE238790T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Semiconductor Memories (AREA)
AT95942961T 1994-12-15 1995-12-12 Verwendung von pramipexole als neuroschutzmittel ATE238790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/357,121 US5650420A (en) 1994-12-15 1994-12-15 Pramipexole as a neuroprotective agent
PCT/US1995/015613 WO1996018395A1 (en) 1994-12-15 1995-12-12 Use of pramipexole as a neuroprotective agent

Publications (1)

Publication Number Publication Date
ATE238790T1 true ATE238790T1 (de) 2003-05-15

Family

ID=23404382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942961T ATE238790T1 (de) 1994-12-15 1995-12-12 Verwendung von pramipexole als neuroschutzmittel

Country Status (16)

Country Link
US (1) US5650420A (de)
EP (1) EP0797439B1 (de)
JP (2) JP4796219B2 (de)
KR (2) KR100420252B1 (de)
CN (1) CN1177586C (de)
AT (1) ATE238790T1 (de)
AU (1) AU712666B2 (de)
CA (1) CA2207323C (de)
DE (1) DE69530606T2 (de)
DK (1) DK0797439T3 (de)
ES (1) ES2197213T3 (de)
MX (1) MX9704377A (de)
NZ (1) NZ298606A (de)
PT (1) PT797439E (de)
SI (1) SI0797439T1 (de)
WO (1) WO1996018395A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
HUP0101803A3 (en) * 1998-05-15 2002-10-28 Upjohn Co New use of cabergoline and pramipexole for preparation of medicaments
EP1591119A3 (de) * 1998-05-15 2007-03-28 Pharmacia & Upjohn Company LLC Pramipexol zur Behandlung von Krankheiten des Zentralnervensystems, insbesondere Parkinson's Krankheit
US6750235B1 (en) 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
WO2002017931A1 (fr) * 2000-09-01 2002-03-07 Xiaomin Wang Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
FR2825087B1 (fr) * 2001-05-22 2005-01-14 Galderma Res & Dev Analogues de la vitamine d
DE10137453A1 (de) * 2001-08-02 2003-02-20 Boehringer Ingelheim Pharma Pramlpexol als Antikonvulsivum
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
MXPA04005572A (es) * 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
US20030166696A1 (en) * 2002-01-24 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexole for the treatment of HIV dementia
DE10203103A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Pramipexol zur Behandlung von HIV Demenz
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
GB0221513D0 (en) 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
WO2005070428A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
WO2006012277A2 (en) * 2004-06-30 2006-02-02 Amr Technology, Inc. Biocatalytic process for preparing enantiomerically enriched pramipexole
EA201001086A1 (ru) 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
WO2007045620A1 (de) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
ITMI20060044A1 (it) * 2006-01-13 2007-07-14 Dipharma Spa Sintesi di intermedi pr la preparazione di pramipexolo
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US20100063116A1 (en) * 2006-10-30 2010-03-11 Boehringer Ingelheim International Gmbh Use of pramipexole or a salt thereof for the treatment of parkinson's disease
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
PT2101766T (pt) * 2006-12-14 2016-12-28 Knopp Biosciences Llc Composições e métodos de utilização de (r)-pramipexole
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
CN102802418A (zh) * 2009-06-19 2012-11-28 诺普神经科学股份有限公司 用于治疗肌萎缩性侧索硬化的组合物和方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2016194015A2 (en) 2015-06-04 2016-12-08 Chiarugi Alberto Use of r(+)-pramipexole (dexpramipexole) for the treatment of cerebral ischemia of the focal type
EP3600291A4 (de) 2017-03-27 2020-12-23 Chase Therapeutics Corporation Zusammensetzungen und verfahren zur behandlung von synucleinopathien
EP4663182A2 (de) 2018-03-16 2025-12-17 Scent Science International Inc. Prophylaktisches oder therapeutisches mittel gegen hypoxische verletzungen, ischämia-reperfusionsverletzungen und entzündungen, zellschutzmittel für transplantationen und biokonservierungsmittel
KR20210118846A (ko) * 2018-12-27 2021-10-01 체이스 테라퓨틱스 코포레이션 돔페리돈 항신경퇴행성 조합 및 사용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung

Also Published As

Publication number Publication date
JP4796219B2 (ja) 2011-10-19
EP0797439A1 (de) 1997-10-01
CA2207323A1 (en) 1996-06-20
ES2197213T3 (es) 2004-01-01
MX9704377A (es) 1998-07-31
NZ298606A (en) 2001-02-23
DE69530606D1 (de) 2003-06-05
PT797439E (pt) 2003-08-29
DE69530606T2 (de) 2004-02-19
JPH10510809A (ja) 1998-10-20
KR100420252B1 (ko) 2004-04-21
JP2007217432A (ja) 2007-08-30
EP0797439B1 (de) 2003-05-02
AU712666B2 (en) 1999-11-11
CN1177586C (zh) 2004-12-01
US5650420A (en) 1997-07-22
KR100451874B1 (ko) 2004-10-08
AU4413496A (en) 1996-07-03
SI0797439T1 (en) 2003-12-31
CN1169677A (zh) 1998-01-07
DK0797439T3 (da) 2003-08-25
CA2207323C (en) 2006-10-10
WO1996018395A1 (en) 1996-06-20
KR20040000443A (ko) 2004-01-03

Similar Documents

Publication Publication Date Title
DE69530606D1 (de) Verwendung von pramipexole als neuroschutzmittel
TR199902516T2 (xx) Kalsilitik bile�imleri.
MX9100804A (es) Derivados de hidroxiurea hipoglucemica
TR199901653T2 (xx) Fitalazinonlar.
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DK1489082T3 (da) Mellemprodukter
EA199800667A1 (ru) Новые фенантридины
TR199501568A2 (tr) Tasikinin öncüleri.
TR28718A (tr) Dinamik takilan tipte cocuk bezi.
EP0621686A3 (de) Verstärker.
ATE167670T1 (de) N-alkylthiopolyaminderivate als radioprotektive mittel
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
FR2714272B3 (fr) Porte-monnaie annulaire.
DE69513864D1 (de) Verwendung von Polyketon /HDPE Mischungen
DK0722501T3 (da) Klonet pullulanase
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
DE59706407D1 (de) Verwendung von polyether-pur für sicherheitskleidung
DE69313554D1 (de) Verwendung von Tetrahydro-4-methyl-2-phenyl-2H-pyran als Riechstoff
DE69023964D1 (de) Verwendung von Isoxazolin-3-one-Derivaten als Antidepressiva.
FR2710245B3 (fr) Composition amaigrissante.
DE69526156D1 (de) Verwendung des 1,3-Undecadien-5-yne als Duftstoff
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
DE59004528D1 (de) Verwendung des (+)-enantiomeren von anipamil.
ATE253562T1 (de) Substituierte 2,4-diamino-1,3,5-triazine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0797439

Country of ref document: EP